Financial statements Izobud
Balance sheet data of IZOBUD
|
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
|---|---|---|---|---|---|---|
| Total assets | 44 428 077,83 | 42 874 286,71 | 53 646 146,97 | 61 280 612,25 | 94 743 892,82 | 103 425 665,53 |
| A. Fixed assets | 20 912 766,73 | 17 896 248,93 | 24 757 409,10 | 27 087 660,67 | 49 134 397,54 | 58 758 569,58 |
| B. Current assets | 23 515 311,10 | 24 978 037,78 | 28 888 737,87 | 34 192 951,58 | 45 609 495,28 | 44 667 095,95 |
| C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| D. Own shares (stocks) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Total liabilities | 44 428 077,83 | 42 874 286,71 | 53 646 146,97 | 61 280 612,25 | 94 743 892,82 | 103 425 665,53 |
| A. Equity | 19 470 619,90 | 20 569 202,38 | 22 398 333,52 | 25 565 894,07 | 35 589 144,28 | 39 252 572,78 |
| B. Liabilities and provisions for liabilities | 24 957 457,93 | 22 305 084,33 | 31 247 813,45 | 35 714 718,18 | 59 154 748,54 | 64 173 092,75 |
| I. Long-term liabilities | 4 037 924,38 | 4 057 944,68 | 6 668 011,37 | 2 865 494,03 | 15 090 900,57 | 13 103 672,65 |
| II. Short-term liabilities | 15 320 542,65 | 13 544 401,29 | 20 764 751,73 | 25 501 077,06 | 36 497 695,90 | 30 538 670,97 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.